In vitro and in vivo results showed that GNS@BSA/I-MMP2 NPs have much better cellular uptake, antitumor (93% tumor volume decrease) efficacy, and only minor organ damage when compared to the free IR 780 iodide and nontargeted IR 780 encapsulated NPs [131]. This evidence concerns the gene MMP2 and neoplasm.